Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244257 · ClinicalTrials.gov registry record · Phase 1
Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
A Phase 1 study, sponsored by Genzyme, a Sanofi Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00244257 is a Phase 1 study that was terminated before completion, run by Genzyme, a Sanofi Company. The registered enrollment target is 10 participants.
The verdict
NCT00244257, a Phase 1 study, was terminated before completion, sponsored by Genzyme, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study is designed to investigate the safety of a single infusion of GMA161 in patients with idiopathic thrombocytopenic purpura, as well as, the way the drug enters and leaves the body. In addition, throughout the study, platelet counts and other blood cell numbers will be measured. NOTE: A decision was made to terminate this study in June 2008 due to low enrollment.
Interventions
- BIOLOGICAL GMA161
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-08 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244257
The ClinicalTrials.gov registry entry for NCT00244257 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GMA161 is the first listed.
NCT00244257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244257 about?
NCT00244257 is a clinical study titled "Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)". This study is designed to investigate the safety of a single infusion of GMA161 in patients with idiopathic thrombocytopenic purpura, as well as, the way the drug enters and leaves the body. In addition, throughout the study, platelet counts and other blood cell numbers will be measured. NOTE: A dec...
What is the current status of trial NCT00244257?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2005-08. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00244257?
The interventions under investigation include: GMA161 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00244257?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.